[Clinicopathological, molecular characteristics and prognostic analysis of non-small cell lung cancer with HER-2 genetic variations].
Lung cancers with HER2 mutations show distinct clinical patterns, potentially enabling better molecular classification before treatment.
A large sequenced lung-cancer cohort described distinct clinical patterns for HER2 mutations and amplifications. The retrospective findings may refine molecular stratification but need external validation before changing treatment.
What the study was
- Study design
- Retrospective molecular cohort study
- Population
- Patients with non-small-cell lung cancer undergoing targeted next-generation sequencing
- Sample size
- 2795
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Zhonghua zhong liu za zhi [Chinese journal of oncology]
Why it surfaced
The cohort is sizable and directly relevant to precision oncology, but the retrospective single-center analysis is prognostic rather than interventional.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.